Literature DB >> 27212245

Role of epithelial to mesenchymal transition in hepatocellular carcinoma.

Gianluigi Giannelli1, Petra Koudelkova2, Francesco Dituri3, Wolfgang Mikulits4.   

Abstract

The epithelial to mesenchymal transition (EMT) is a multistep biological process whereby epithelial cells change in plasticity by transient de-differentiation into a mesenchymal phenotype. EMT and its reversal, mesenchymal to epithelial transition (MET), essentially occur during embryogenetic morphogenesis and have been increasingly described in fibrosis and cancer during the last decade. In carcinoma progression, EMT plays a crucial role in early steps of metastasis when cells lose cell-cell contacts due to ablation of E-cadherin and acquire increased motility to spread into surrounding or distant tissues. Epithelial plasticity has become a hot issue in hepatocellular carcinoma (HCC), as strong inducers of EMT such as transforming growth factor-β are able to orchestrate both fibrogenesis and carcinogenesis, showing rising cytokine levels in cirrhosis and late stage HCC. In this review, we consider the significance of EMT-MET in malignant hepatocytes as well as changes in the plasticity of hepatic stellate cells for cellular heterogeneity of HCC, and further aim at explaining the current limiting insights into EMT by snapshot analyses of HCC tissues. Recent advances in the identification of clinically relevant mechanisms that impinge on important EMT-transcription factors, as well as on miRNAs causing EMT signatures and HCC progression are highlighted. In addition, we draw particular attention to framing EMT in the context of potential clinical relevance for HCC patients. We conclude that some aspects of EMT are still elusive and further studies are required to better link the clinical management of HCC with biomarkers and targeted therapies related to EMT.
Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cell invasion; EMT; Epithelial plasticity; HCC; MET; Patient survival; Therapy; Tumor heterogeneity

Mesh:

Substances:

Year:  2016        PMID: 27212245     DOI: 10.1016/j.jhep.2016.05.007

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  177 in total

1.  A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellular carcinoma.

Authors:  Colin M Court; Shuang Hou; Paul Winograd; Nicholas H Segel; Qingyu Wilda Li; Yazhen Zhu; Saeed Sadeghi; Richard S Finn; Ekambaram Ganapathy; Min Song; Samuel W French; Bita V Naini; Shonan Sho; Fady M Kaldas; Ronald W Busuttil; James S Tomlinson; Hsian-Rong Tseng; Vatche G Agopian
Journal:  Liver Transpl       Date:  2018-07       Impact factor: 5.799

2.  Prognostic value of multiple epithelial mesenchymal transition-associated proteins in intrahepatic cholangiocarcinoma.

Authors:  Xiangguo Tian; Zhixin Cao; Qian Ding; Zhen Li; Chunqing Zhang
Journal:  Oncol Lett       Date:  2019-06-24       Impact factor: 2.967

Review 3.  Angiogenesis, Invasion, and Metastasis Characteristics of Hepatocellular Carcinoma.

Authors:  Şirin Yüksel; Cemaliye Boylu Akyerli; M Cengiz Yakıcıer
Journal:  J Gastrointest Cancer       Date:  2017-09

4.  The TGF-β pathway: a pharmacological target in hepatocellular carcinoma?

Authors:  Isabel Fabregat; Gianluigi Giannelli
Journal:  Hepat Oncol       Date:  2017-07-06

5.  Long non-coding RNA UCA1 regulates the expression of Snail2 by miR-203 to promote hepatocellular carcinoma progression.

Authors:  Ji-Nan Xiao; Ting-Hua Yan; Rui-Ming Yu; Yi Gao; Wen-Long Zeng; Sui-Wan Lu; Hua-Xing Que; Ze-Ping Liu; Jin-Hua Jiang
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-08       Impact factor: 4.553

Review 6.  The functional role of exosome in hepatocellular carcinoma.

Authors:  Hongyu Liu; Baoguo Li
Journal:  J Cancer Res Clin Oncol       Date:  2018-07-30       Impact factor: 4.553

7.  Thymidine phosphorylase promotes metastasis and serves as a marker of poor prognosis in hepatocellular carcinoma.

Authors:  Qiang Zhang; Yang Zhang; Xuejiao Hu; Yuan Qin; Weilong Zhong; Jing Meng; Ting Xiao; Chunhong Zhang; Meng Li; Shuang Chen; Huijuan Liu; Yanrong Liu; Tao Sun; Cheng Yang
Journal:  Lab Invest       Date:  2017-05-22       Impact factor: 5.662

8.  Molecular crosstalk between Y5 receptor and neuropeptide Y drives liver cancer.

Authors:  Peter Dietrich; Laura Wormser; Valerie Fritz; Tatjana Seitz; Monica De Maria; Alexandra Schambony; Andreas E Kremer; Claudia Günther; Timo Itzel; Wolfgang E Thasler; Andreas Teufel; Jonel Trebicka; Arndt Hartmann; Markus F Neurath; Stephan von Hörsten; Anja K Bosserhoff; Claus Hellerbrand
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

9.  TGFβ signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells.

Authors:  Nathan Ungerleider; Chang Han; Jinqiang Zhang; Lu Yao; Tong Wu
Journal:  Mol Carcinog       Date:  2016-11-25       Impact factor: 4.784

10.  The influence of the long-term chemical activation of the nuclear receptor pregnane X receptor (PXR) on liver carcinogenesis in mice.

Authors:  Ryota Shizu; Mai Ishimura; Sumihito Nobusawa; Takuomi Hosaka; Takamitsu Sasaki; Satoru Kakizaki; Kouichi Yoshinari
Journal:  Arch Toxicol       Date:  2021-01-04       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.